Life Sciences: Our May 2026 expert analysis
The EU regulatory landscape for the life sciences sector continues to evolve at pace. During May, the Life Sciences Group at McCann FitzGerald examined five key developments shaping industry compliance and strategy. Click the links below to access the full expert analysis on each topic, and please reach out to Niall Best, Conor Cunningham, Ciara O’Herlihy or your usual McCann FitzGerald contact for further information.
Is the polluter paying? European challenges to the revised Urban Waste Water Treatment Directive
What counts as ‘scientific research’ under the GDPR? EDPB consults on Scientific Research Guidelines
Clinical Trials and the EU Biotech Act: Key Takeaways from the EDPB - EDPS Joint Opinion
EU Critical Medicines Act: Political agreement reached – what life sciences companies need to know
When does the Clock Start? Key Takeaways from the CJEU’s recent Sanofi Pasteur judgment
This document has been prepared by McCann FitzGerald LLP for general guidance only and should not be regarded as a substitute for professional advice. Such advice should always be taken before acting on any of the matters discussed.
Select how you would like to share using the options below